Status:
UNKNOWN
Halodine Nasal Antiseptic in Patients With COVID-19
Lead Sponsor:
Halodine LLC
Conditions:
SARS-CoV-2 Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Povidone iodine (PVP-I) is a well-known broad spectrum, resistance free antimicrobial agent that has a long history of safe and effective use. Halodine Nasal Antiseptic is formulated for topical appli...
Detailed Description
This is a multicenter, phase 4 prospective, single-cohort study in adult male and female volunteers hospitalized with COVID-19. Baseline nasopharyngeal swabs will be performed on all individuals. Halo...
Eligibility Criteria
Inclusion
- Hospitalized with COVID-19
- Positive SARS-CoV-2 (rRT)-PCR within 48 hours of enrollment
Exclusion
- Allergies to iodine-containing compounds
Key Trial Info
Start Date :
April 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2021
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04517188
Start Date
April 1 2021
End Date
July 1 2021
Last Update
February 10 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.